Document Type: Review Article

Authors

1 Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

3 Nephrology-Urology Research Center and Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Nephrotoxicity is generally considered as the most clinically significant and dose-limiting adverse reaction of amphotericin B. Currently, only the clinical effectiveness of salt loading and administering lipid formulations of amphotericin B have been clearly demonstrated to prevent its nephrotoxicity. In this review, we collected the published data related to dopamine receptor agonists in preventing amphotericin B nephrotoxicity. A literature search was conducted by the relevant keywords like ‘‘amphotericin B”, “nephrotoxicity’’, and ‘‘dopamine’’ in databases such as Scopus, Medline, Embase and ISI Web of Knowledge. Four relevant articles were considered. Results of all the 3 experimental studies demonstrated that co-administration of dopamine (0.5-10 μg/kg/min) as continuous intravenous infusion, SK&F R-105058 (10 mg/kg twice daily), a prodrug of fenoldopam, orally, or fenoldopam, a relatively selective dopamine receptor type 1 agonist, (0.5 or 1 μg/kg/min) as continuous intravenous infusion can at least significantly mitigate the decrease in creatinine clearance caused by amphotericin B. Furthermore, fenoldopam and SK&F R-105058 can also protect against or delay amphotericin B-induced tubular damages. In contrast, the only clinical trial published until now found that simultaneous continuous intravenous infusion of low dose dopamine (3 μg/kg/min) had no beneficial effects on the incidence, severity, as well as time onset of developing amphotericin B-induced nephrotoxicity in autologous bone marrow transplant and leukemia patients. Considering the lack of beneficial effects in different settings such as acute kidney injury of any cause, negative results of the only clinical trial, and risk of significant adverse reactions, continuous intravenous infusion of low dose dopamine (1-3 μg/kg/min) or selective dopamine receptor type 1 agonists (e.g., fenoldopam) currently appears to have no real clinical role in preventing or attenuating amphotericin B nephrotoxicity.

  1. - Sheppard D, Lampiris HW. Antifungal Agents. In: Katzung B, Masters S, Trevor A (eds). Basic and Clinical Pharmacology, 12 edition. New York: McGraw-Hill Medical, 2011.
  2. - Laniado-Laborı´n R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev beroam Micol 2009;26:223-7.
  3. - Bennett JE. Antimicrobial agents: antifungal agents. In: Brunton L, Chabner B, Knollman B (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12 edition. New York: McGraw-Hill Professional, 2010.
  4. - Ulozas E. Amphotericin B-induced nephrotoxicity. Compr Toxicol 2010;7:347-57.
  5. - Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am J Med 1984;77:471-4.
  6. - Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Platt R. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001;60:1452-9.
  7. - Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
  8. - Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111: 528-34.
  9. - Tavakoli-Ardakani M, Eshraghi A, Hajhossein Talasaz A, Salamzadeh J. A drug utilization evaluation study of amphotericin B in neutropenic patients in a teaching hospital in Iran. Iran J Pharm Res 2012;11:151-6.
  10. - Hayatshahi A, Javadi MR, Torkamandi H, Hadjibabaie M, Hanafi S, Gholami K, Alimoghaddam K, Iravani M, Ghavamzadeh A. Drug utilization review of conventional amphotericin B in febrile neutropenic patients hospitalized at a bone marrow transplant center. IJHOSCR 2010; 4:1-3.
  11. - Khalili H, Bairami S, Kargar M. Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome. Acta Med Iran 2013;51:871-8.
  12. - Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother 2000;34:94-7.
  13. - Atsmon J, Dolev E. Drug-induced hypomagnesaemia : scope and management. Drug Saf 2005;28:763-88.
  14. - Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000;12:463-70.
  15. - Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 2004;26:421-6.
  16. - Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 2009;5:193-202.
  17. - Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ, Viscoli C; Amphotericin B Systematic Review Study. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-320.
  18. - Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? Expert Opin Drug Saf 2012;11:969-83.
  19. - Karimzadeh I, Khalili H, Farsaei S, Dashti-Khavidaki S, Sagheb MM. Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity. Eur J Clin Pharmacol 2013;69:1351-68.
  20. - Karimzadeh I, Khalili H, Sagheb MM, Farsaei S. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity. Expert Opin Drug Metab Toxicol. 2015, In press.
  21. - KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(Suppl 1):8. Available at: www.kdigo.org/clinical...guidelines/.../KDIGO%20AKI%20Guideline. [Accessed Jan 20, 2014].
  22. - Reiner NE, Thompson WL. Dopamine and saralasin antagonism of renal vasoconstriction and oliguria caused by amphotericin B in dogs. J Infect Dis 1979;140:564-75.
  23. - Brooks DP, Mitchell MP, Short BG, Ruffolo RR Jr, Nichols AJ. Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058. J Pharmacol Exp Ther 1991;257:1243-7.
  24. - Nichols AJ, Koster PF, Brooks DP, Ruffolo RR Jr. Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Ther 1992;260:269-74.
  25. - Camp MJ, Wingard JR, Gilmore CE, Lin LS, Dix SP, Davidson TG, Geller RB. Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients. Antimicrob Agents Chemother 1998;42:3103-6.
  26. - Denton MD, Chertow GM, Brady HR. Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
  27. - Schwartz LB, Gewertz BL. The renal response to low dose dopamine. J Surg Res 1988; 45: 574-88.
  28. - Steinhausen M, Weis S, Fleming J, Dussel R, Parekh N. Responses of in vivo renal microvessels to dopamine. Kidney Int 1986;30:361-70.
  29. - Satoh T, Ominato M, Katz AI. Different mechanisms of renal Na-K-ATPase regulation by dopamine in the proximal and distal nephron. Hypertens Res 1995; 18 Suppl 1: S137-40.
  30. - Krishna GG, Danovitch GM, Beck FW, Sowers JR. Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med 1985;105:214-8.
  31. - Abay MC, Reyes JD, Everts K, Wisser J. Current literature questions the routine use of low-dose dopamine. AANA J 2007; 75: 57-63.
  32. - McDonald RH, Goldberg LI, McNay JL, Tuttle EP Jr. Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest 1964; 43: 1116-24.
  33. - McNay JL, McDonald RH, Goldberg LI. Direct vasodilation produced by dopamine in the dog. Circ Res 1965; 16: 510-7.
  34. - Olsen NV, Lund J, Jensen PF, Espersen K, Kanstrup IL, Plum I, Leyssac PP. Dopamine, dobutamine, and dopexamine. A comparison of renal effects in unanesthetized human volunteers. Anesthesiology 1993; 79: 685-94.
  35. - Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139-43.
  36. - Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29: 1526-31.
  37. - Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med 2002; 28: 877-83.
  38. - Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510-24.
  39. - Allison NL, Dubb JW, Ziemniak JA, Alexander F, Stote RM. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 1987;41:282-8.
  40. - Murray PT. Fenoldopam: renal-dose dopamine redux? Crit Care Med 2006; 34: 910-1.
  41. - Palevsky PM, Murray PT. Acute kidney injury and critical care nephrology. NephSAP 2006; 5: 72-120.
  42. - Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabrò MG, Ranucci M, Zangrillo A. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007;49:56-68.
  43. - Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
  44. - Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, Wilensky RL, O'Neill WW; CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003 5;290:2284-91.
  45. - Schnermann J, Todd KM, Briggs JP. Effect of dopamine on the tubuloglomerular feedback mechanism. Am J Physiol 1990; 258: F790-8.
  46. - Larson TS, Hudson K, Mertz JI, Romero JC, Knox FG. Renal vasoconstrictive response to contrast media. The role of sodium balance and the renin-angiotensin system. J Lab Clin Med 1983;101:385-91.
  47. - Heyman SN, Brezis M, Reubinoff CA, Greenfeld Z, Lechene C, Epstein FH, Rosen S. Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988;82:401-12.
  48. - Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for preventing of contrastinduced nephropathy in diabetic patients: A randomized study. Indian Heart J 1999;51:521-6.